Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Zenas to Start China Trials of Thyroid Eye Disease Therapy

publication date: Aug 3, 2022

Zenas BioPharma was approved to start a China Phase I/II clinical trial of treatment for thyroid eye disease therapy (TED). ZB001 is a mAb that targets insulin-like growth factor 1 receptor (IGF-1R). TED is a vison-threatening autoimmune disease that causes inflammation and fibrosis within the orbit of the eye, a condition without any approved therapies in China. TED is usually treated by high doses of steroids (which are associated with serious side effects) or surgery. With operations in Boston and Shanghai, Zenas develops immune-based therapies for patients in the US, China and globally. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
November 8-11, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022